pilldic.Your medicine dictionary
Text size
← US medicines
US · Over-the-counter medicine

Obagi-C Rx System C-SunguardSPF 30

Dosage form
CREAM
Labeler
OMP, Inc.
Label updated
2019-09-17
Retrieved
2026-09-07
Active ingredients
OCTINOXATE · ZINC OXIDE
View original label and images on DailyMed ↗
Label information

Drug Facts

Active ingredients

Octinoxate, 7.5%, Zinc oxide, 9%

Purpose

Sunscreens

Uses
  • •Helps prevent sunburn.
  • •Higher SPF gives more sunburn protection.
Warnings
  • For external use only.

When using this product

  • •Keep out of eyes. Rinse with water to remove.

Stop use and ask a doctor if

  • •Rash or irritation develops and lasts.

Keep out of the reach of children

If swallowed, get medical help or contact a Poison Control Center right away.

Directions
  • •Apply generously and evenly 15 minutes before sun exposure.
  • •Children under six months of age: ask a doctor.
  • •Reapply as needed or after towel drying, swimming or perspiring.
Other information
  • •Store at controlled room temperature: 15°-30°C (59°-86°F).
  • •High sun protection product.
  • •Sun alert: Limiting sun exposure, wearing protective clothing, and using sunscreens may reduce the risks of skin aging, skin cancer, and other harmful effects of the sun.
Inactive ingredients

butylparaben, cetearyl alcohol, citric acid, C13-14 isoparaffin, diethanolamine cetyl phosphate, disodium edetate, ethylparaben, isobutylparaben, isopropyl palmitate, laureth-7, methylparaben, octyl stearate, phenoxyethanol, polyacrylamide, polyether-1, polysorbate 60, propylparaben, purified water, sodium hydroxide, triethoxycaprylysilane.

Label information

Dist. by OMP, Inc. Long Beach, CA 90802

PRINCIPAL DISPLAY PANEL - 90 mL Bottle Carton

OBAGI-C
RX SYSTEM

RECOMMENDED
SKIN
CANCER
FOUNDATION
RECOMMENDED AS AN
EFFECTIVE UV SUNSCREEN

C-SUNGUARD
SPF 30

BROAD-SPECTRUM
UVA / UVB SUNSCREEN

AM

3 FL. OZ. (90 mL)

[Image in the official label — see DailyMed source]

DailyMed Set ID: 7b4aa8b4-124c-4e26-9a0a-d200867c3d11 · Version 4
NDC: 62032-107